Clinical Predictors of Functional Cure in Children 1-6 Years-old with Chronic Hepatitis B

Pan, Jing1,2; Wang, Haiyan3,4; Yao, Tiantian1; Liao, Xuejiao3,4; Cheng, Hao1; Liangpunsakul, Suthat5; Wang, Yan1; Zhang, Min2; Zhang, Zheng3,4

2022

10.14218/JCTH.2021.00142

Journal of Clinical and Translational Hepatology   影响因子和分区

2225-0719

2310-8819

Background and Aims: Hepatitis B surface antigen (HB-sAg) clearance is significantly more common in children with chronic hepatitis B (CHB) than in adults; however, the possible influencing factors related to HBsAg loss have yet to be found. This study aimed to explore the efficacy of long-term interferon (IFN)alpha therapy in treating children with CHB and analyzed the factors influencing functional cure after treatment. Methods: A total of 236 children aged 1-6 years and diagnosed with CHB via liver biopsy were included in the study, all receiving IFN alpha treatment (IFN alpha-2b monotherapy, IFN alpha-2b followed by lamivudine [LAM] or IFN alpha-2b combined with LAM) and followed up for 144 weeks. A comprehensive analysis was conducted on clinical data, including biochemical items, serum markers of hepatitis B virus (HBV) and immunological indexes, and logistic regression analysis was used to screen the influenc -ing factors related to HBsAg loss. Results: The cumula-tive loss rates of HBsAg were 79.5%, 62.1% and 42.1% at 144 weeks after the start of treatment in the 1-3 years-old group, 3-5 years-old group and 5-7 years-old group, respectively (p<0.05). IFN alpha-2b combined with LAM treat-ment displayed the highest HBsAg loss rates compared with monotherapy and sequential treatment (p=0.011). Younger baseline age and lower HBsAg levels were inde-pendent factors for the prediction of HBsAg loss (p<0.05). The baseline PreS1 and hepatitis B core antibody levels in the HBsAg loss group were lower than those in the HBsAg non-loss group. In addition, the PreS1 level was positively corelated with the level of HBsAg, HBV DNA and liver in-flammation. Conclusions: Long-term treatment with IFN alpha was effective in achieving HBsAg loss in CHB children aged 1-6 years-old. Age less than 3 years-old and lower HBsAg levels are independent predictors of functional cure in chil-dren with CHB.

Chronic hepatitis B Children interferon IFN Therapeutic efficacy Lymphocytes Predictors

SCI

英语

通讯

National Science and Technology Major Project of the Infectious Diseases[2018ZX10301404] ; Shenzhen Science and Technology Innovation Committee[JCYJ2019 0809160213289]

Gastroenterology & Hepatology

Gastroenterology & Hepatology

WOS:000794133100001

XIA & HE PUBLISHING INC

Web of Science

1.Peking Univ First Hosp, Dept Infect Dis, Beijing, Peoples R China
2.Gen Hosp PLA, Liver Dis Dept, Med Ctr 5, Beijing, Peoples R China
3.Shenzhen Third Peoples Hosp, Inst Hepatol, Natl Clin Res Ctr Infect Dis, Shenzhen, Peoples R China
4.Southern Univ Sci & Technol, Sch Med, Affiliated Hosp 2, Shenzhen, Guangdong, Peoples R China
5.Indiana Univ, Div Gastroenterol & Hepatol, Dept Med, Indianapolis, IN USA

Pan, Jing,Wang, Haiyan,Yao, Tiantian,et al. Clinical Predictors of Functional Cure in Children 1-6 Years-old with Chronic Hepatitis B[J]. Journal of Clinical and Translational Hepatology,2022.

Pan, Jing.,Wang, Haiyan.,Yao, Tiantian.,Liao, Xuejiao.,Cheng, Hao.,...&Zhang, Zheng.(2022).Clinical Predictors of Functional Cure in Children 1-6 Years-old with Chronic Hepatitis B.Journal of Clinical and Translational Hepatology.

Pan, Jing,et al."Clinical Predictors of Functional Cure in Children 1-6 Years-old with Chronic Hepatitis B".Journal of Clinical and Translational Hepatology (2022).